Diabetes Drug Termination By Hyperion Therapeutics Leads to Legal Investigtion By Kirb y McInerney

Kirby McInerney LLP is investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. (“Hyperion” or the “Company”) (NASDAQ:HPTX) concerning the termination of the development of its Type 1 diabetes drug due to the manipulation of trial data.

On September 8, 2014, the Company announced that it is terminating development of DiaPep277 for newly diagnosed Type 1 diabetes. In a press release, the Company noted that it “has uncovered evidence that certain employees of Andromeda Biotech, Ltd., which Hyperion acquired in June 2014, engaged in serious misconduct, including collusion with a third-party biostatistics firm in Israel to improperly receive un-blinded DIA-AID 1 trial data and to use such data in order to manipulate the analyses to obtain a favorable result. Additional evidence indicates that the biostatistics firm and certain Andromeda employees continued the improper practice of sharing and examining un-blinded data from the ongoing DIA-AID 2 trial.”

On this news, shares of Hyperion fell $2.33 per share to $25.31, or more than 8.43%, in intraday trading on September 8, 2014.

If you are a Hyperion stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at, or telephone at (212) 699-1145, Melissa Fortunato, Esq. by email at, or telephone at (212) 699-1141, or toll free at (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, whistleblower, antitrust and consumer litigation. For additional information, please go to

NYC Medicaid Reimumbursement Unit Employee Guilty of Million Dollar Medicaid Fraud

Uria Menendez and Best Friend Firms Announce Latin America Law Merger